- cafead Dec 11, 2023 at 10:32: AM
via Just as the FDA revisits two accelerated approvals in peripheral T cell lymphoma (PTCL), AstraZeneca spinout Dizal Pharmaceutical is charting its own path for a potential conditional nod in the blood cancer.
The Chinese biotech has phase 2 tumor response data for its JAK1 inhibitor golidocitinib that, as CEO Xiaolin Zhang, Ph.D., pointed out, look better than readouts from existing therapies in previously treated PTCL.
article source
The Chinese biotech has phase 2 tumor response data for its JAK1 inhibitor golidocitinib that, as CEO Xiaolin Zhang, Ph.D., pointed out, look better than readouts from existing therapies in previously treated PTCL.
article source